Enhancing CAR-T cell therapy against solid tumor by drug-free triboelectric immunotherapy
Source abstract
Abstract
Chimeric antigen receptor (CAR) T cell therapy is a highly effective immunotherapy for hematological tumors, but its efficacy against most solid tumors remains challenging. Herein, a novel synergistic combination therapy of drug-free triboelectric immunotherapy and CAR-T cell therapy against solid tumor was proposed. A triboelectric nanogenerator (TENG) that can generate pulsed direct-current by coupling triboelectrification effect and electrostatic breakdown effect was fabricated. The TENG can generate up to 30 pulse direct-current peaks with peak current output ≈35 μA in a single sliding to power the triboelectric immunotherapy. The pulsed direct-current stimulation induced immunogenic cell death of tumor cells (survival rate of 35.9 %), which promoted dendritic cells maturation, accelerated the process of antigen presentation to CAR-T cells and enhanced the systemic adaptive immune response. Furthermore, triboelectric immunotherapy promoted M1-like macrophage polarization, reduced regulatory T cells differentiation and reprogrammed the tumor immunosuppressive microenvironment, which ultimately enhanced the efficacy of CAR-T cells to eradicate nearly 60 % of NALM6 solid tumor mass. Notably, considering that triboelectric immunotherapy is a safe and effective drug-free antitumor strategy, the combined therapy did not increase the burden of double-medication on patients.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: CAR-T cell therapy research · Nanowire Synthesis and Applications · Viral Infectious Diseases and Gene Expression in Insects
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (46)
Show source-provided references
1. Engineering CAR-T cells for next-generation cancer therapy10.1016/j.ccell.2020.07.005 ↗
2. Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells10.1038/s41587-022-01245-x ↗
3. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia10.1056/NEJMoa1709919 ↗
4. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy10.1038/s41467-023-37874-2 ↗
5. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor10.1038/nbt.4086 ↗
6. Targeted calcium influx boosts cytotoxic T lymphocyte function in the tumour microenvironment
7. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells10.1016/j.immuni.2023.09.001 ↗
8. The role of exhaustion in CAR T cell therapy10.1016/j.ccell.2021.06.012 ↗
9. Adoptive cell transfer as personalized immunotherapy for human cancer10.1126/science.aaa4967 ↗
10. CAR T cells ready to go mainstream10.1038/nrclinonc.2016.99 ↗
11. Born to survive: how cancer cells resist CAR T cell therapy10.1186/s13045-021-01209-9 ↗
12. CAR-T cell therapy: current limitations and potential strategies10.1038/s41408-021-00459-7 ↗
13. Navigating CAR-T cells through the solid-tumour microenvironment10.1038/s41573-021-00189-2 ↗
14. Engineering strategies to overcome the current roadblocks in CAR T cell therapy10.1038/s41571-019-0297-y ↗
15. Nattokinase-mediated regulation of tumor physical microenvironment to enhance chemotherapy, radiotherapy, and CAR-T therapy of solid tumor10.1021/acsnano.2c12463 ↗
16. Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model10.1080/2162402X.2020.1757360 ↗
17. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses10.1172/jci.insight.99573 ↗
18. Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers10.1158/1078-0432.CCR-17-0432 ↗
19. CAR T therapy beyond cancer: the evolution of a living drug10.1038/s41586-023-06243-w ↗
20. Engineering-enhanced CAR T cells for improved cancer therapy10.1038/s43018-021-00241-5 ↗
21. Triboelectric immunotherapy using electrostatic-breakdown induced direct-current10.1016/j.mattod.2023.02.026 ↗
22. Landscape of cancer cell therapies: trends and real-world data10.1038/d41573-022-00095-1 ↗
23. A constant current triboelectric nanogenerator arising from electrostatic breakdown
24. Combination of irreversible electroporation and STING agonist for effective cancer immunotherapy10.3390/cancers12113123 ↗
25. Irreversible electroporation: an emerging immunomodulatory therapy on solid tumors10.3389/fimmu.2021.811726 ↗
26. T‐cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer10.1002/ctm2.39 ↗
27. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer10.1038/s41467-019-08782-1 ↗
28. A near-infrared-II fluorescent nanocatalyst for enhanced CAR T cell therapy against solid tumor by immune reprogramming10.1021/acsnano.3c02592 ↗
29. High-voltage electrical pulses in oncology: irreversible electroporation, electrochemotherapy, gene electrotransfer, electrofusion, and electroimmunotherapy10.1148/radiol.2020192190 ↗
30. Irreversible electroporation plus allogenic Vγ9Vδ2 T cells enhances antitumor effect for locally advanced pancreatic cancer patients10.1038/s41392-020-00260-1 ↗
31. A noble AuPtAg‐GOx nanozyme for synergistic tumor immunotherapy induced by starvation therapy‐augmented mild photothermal therapy
32. In situ engineering of tumor-associated macrophages via a nanodrug-delivering-drug (β‐Elemene@Stanene) strategy for enhanced cancer chemo-immunotherapy10.1002/anie.202312436 ↗
33. Combination of cryo-shocked M1 macrophages and lonidamine nanodrugs enables potent chemo-immunotherapy
34. In situ reprogramming of tumor-associated macrophages with internally and externally engineered exosomes
35. Reprogramming hypoxic tumor-associated macrophages by nanoglycoclusters for boosted cancer immunotherapy10.1002/adma.202211332 ↗
36. Inosine‐based supramolecular hydrogel for highly efficient PD‐L1 blockade therapy via mediating CD8+ T Cells
37. An ionic liquid ablation agent for local ablation and immune activation in pancreatic cancer
38. Nano ultrasound contrast agent for synergistic chemo-photothermal therapy and enhanced immunotherapy against liver cancer and metastasis10.1002/advs.202300878 ↗
39. In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy10.1038/s41467-021-23316-4 ↗
40. Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models10.1038/s41467-023-40852-3 ↗
41. Highly efficient GSH-responsive "Off-On" NIR-II fluorescent Fenton nanocatalyst for multimodal imaging-guided photothermal/chemodynamic synergistic cancer therapy10.1021/acs.analchem.2c01738 ↗
42. Remodeling of tumor microenvironment by tumor-targeting nanozymes enhances immune activation of CAR T cells for combination therapy
43. Theranostic near-infrared-IIb emitting nanoprobes for promoting immunogenic radiotherapy and abscopal effects against cancer metastasis10.1038/s41467-021-27485-0 ↗
44. Biomimetic nanoplatform loading type I aggregation-induced emission photosensitizer and glutamine blockade to regulate nutrient partitioning for enhancing antitumor immunotherapy10.1021/acsnano.2c02605 ↗
45. Noninvasively immunogenic sonodynamic therapy with manganese protoporphyrin liposomes against triple-negative breast cancer10.1016/j.biomaterials.2020.120639 ↗
46. Nanomessenger-mediated signaling cascade for antitumor immunotherapy10.1021/acsnano.1c02765 ↗